Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Abstract Background: Functional cure through HBsAg loss is a key treatment goal in chronic hepatitis B (CHB), yet its impact on hepatocellular carcinoma (HCC) risk remains incompletely characterized, especially when achieved via interferon (IFN)-based therapy. We aimed to evaluate the HCC risk reduction associated with IFN-based therapy in low-HBsAg CHB patients and develop a validated prediction model for this population.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.